To the wider public and even governments, big data, predictive analytics and machine learning might appear to be recent phenomena that suddenly hold the answers to most of the health care delivery problems. But those who have been generating the debate and charting future adoption over the past several years know it is not as simple as that.
February's Big Data and Analytics in Healthcare forum in London was another opportunity to gauge how far the industry has come – and how far it still has to go – before digital health is an everyday reality for patients.
A high-caliber audience, assembled for Corporate Parity’s second annual forum on this ground-breaking theme, broached big data’s potential to deliver...
A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.
Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.
MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.
In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.
Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.
